Product image of Nefrocarnit (Levocarnitine) supplied by GNH India

Nefrocarnit

Active Ingredient:
Levocarnitine
Origin:
EU

Nefrocarnit (Levocarnitine)

Levocarnitine, the active ingredient in Nefrocarnit, is a carnitine supplement presented as an intravenous solution for parenteral use. It is indicated for primary carnitine deficiency, secondary carnitine deficiency, and metabolic disorders that require carnitine supplementation to support fatty‑acid oxidation in patients of all ages.

GNH India supplies Nefrocarnit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for import. Customers benefit from reliable logistics and technical support.

Manufacturer / TM Owner

Medice Arzneimittel Pütter Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nefrocarnit is used to address carnitine deficiency states and related metabolic disorders.

  • Primary carnitine deficiency: restores intracellular carnitine levels to improve fatty‑acid oxidation and energy production.
  • Secondary carnitine deficiency: supplements depleted carnitine pools caused by renal loss, certain medications, or metabolic stress.
  • Metabolic disorders requiring carnitine supplementation: supports patients with organic acidemias or fatty‑acid oxidation disorders by facilitating mitochondrial transport of long‑chain fatty acids.

How It Works

  • Levocarnitine acts as a carrier molecule that transports long‑chain fatty acids across the inner mitochondrial membrane. By forming acyl‑carnitine esters, it enables β‑oxidation of fatty acids, thereby generating acetyl‑CoA for the citric acid cycle and ATP production. The increased availability of carnitine also assists in the removal of excess acyl groups, helping to maintain metabolic homeostasis. This mechanism underlies its therapeutic role in conditions where endogenous carnitine stores are insufficient.

Side Effects

Intravenous levocarnitine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea: mild to moderate feeling of sickness.
  • Injection site reactions: redness, swelling, or pain at the infusion site.
  • Headache: transient cranial discomfort.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
  • Cardiac arrhythmias: irregular heart rhythm potentially linked to electrolyte shifts.
  • Metabolic acidosis: significant pH reduction in blood.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

  • Renal impairment: adjust dose and monitor plasma carnitine levels.
  • Hepatic impairment: use with caution; monitor liver function tests.
  • Pediatric use: safety not fully established; consider risk‑benefit.
  • Concomitant valproic acid therapy: increased risk of hyperammonemia; monitor ammonia.
  • Monitor for hypersensitivity: observe for rash, bronchospasm, or anaphylaxis.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levocarnitine may interact with other medicines; review the following.

Major Interactions (Avoid)

  • Valproic acid: may increase risk of hyperammonemia and reduce efficacy.
  • Dialysis: extracorporeal removal can markedly decrease plasma levocarnitine levels.
  • Anticonvulsants (e.g., phenobarbital): may accelerate carnitine metabolism, lowering therapeutic effect.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): levocarnitine may potentiate anticoagulant effect; monitor INR.
  • Thyroid hormone replacement: possible alteration of metabolic rate; assess thyroid function.
  • Diuretics (loop): may affect electrolyte balance; watch for hypotension.

Frequently Asked Questions

Nefrocarnit provides levocarnitine, a carnitine supplement used to treat primary and secondary carnitine deficiency and to support patients with metabolic disorders that benefit from enhanced fatty‑acid oxidation.

Levocarnitine transports long‑chain fatty acids into mitochondria by forming acyl‑carnitine complexes, enabling β‑oxidation and ATP generation while also helping to clear excess acyl groups, thereby supporting overall energy metabolism.

The appropriate dose of Nefrocarnit is determined by the prescribing clinician based on the patient’s condition, age, weight, renal function and other clinical factors. No fixed regimen is provided in public literature.

Safety data for levocarnitine during pregnancy and lactation are limited. The decision to use Nefrocarnit in these situations should be made by the treating physician after weighing potential benefits against unknown risks.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Nefrocarnit contains the same active ingredient, levocarnitine, as other carnitine preparations but is supplied as an injectable solution intended for intravenous administration. Oral formulations differ in absorption profile, while Nefrocarnit offers rapid systemic availability suitable for acute or severe deficiency states.

The product should be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or particulate.

Nefrocarnit is given by intravenous infusion. The exact infusion rate and duration are prescribed by the treating clinician, typically administered through a sterile infusion set under aseptic conditions in a clinical setting.

The most serious adverse events include anaphylaxis, severe hypersensitivity reactions, cardiac arrhythmias, and metabolic acidosis. Prompt recognition and immediate medical intervention are essential if any of these events occur.

Patients with known hypersensitivity to levocarnitine or any component of the formulation should avoid Nefrocarnit. Caution is also advised for individuals with severe renal impairment, uncontrolled cardiac disease, or those receiving medications that may precipitate serious interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levocarnitine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT